Albany Molecular Research Inc. (AMRI) announced the company’s manufacturing facility in Rensselaer, NY has been designated “Industry Leader” as part of its re-certification under the SafeBridge® program for "Potent Compound Safety Certification."
The facility is the first in the industry to achieve Leader Status based on quantitative results of the Potent Compound Safety Certification program administered by SafeBridge. Certification confirms that AMRI not only meets the standards identified to be an Industry Leader for the safe handling of potent active pharmaceutical ingredients (APIs), but that currently AMRI holds the top position for potent compound safety in the industry category for this classification.
SafeBridge conducted a 60-element review of health and safety programs, procedures, exposure controls, and process containment of synthetic chemistry operations with occupationally potent APIs at the Rensselaer site.
“This accomplishment emphasizes our commitment to excellence and advancing the industry standard for highly potent manufacturing,” said John Ratliff, CEO. “I am so proud of our team at Rensselaer for being the first in the industry to earn leader status from SafeBridge for our high potency capabilities.”